Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study

American Journal of Medicine

Volumn 129, Issue 3, 2016, Pages 299-306.e2

  Larsen, Kasper Søltoft ^a,b   Pottegård, Anton ^b   Lindegaard, Hanne M ^a   Hallas, Jesper ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Allopurinol; Cardiovascular outcomes; Gout; Hyperuricemia

Indexed keywords

ALLOPURINOL; URATE; ANTIGOUT AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPARATIVE STUDY; DENMARK; DRUG EFFECT; FEMALE; GOUT; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; URIC ACID BLOOD LEVEL; URIC ACID NEPHROPATHY; CARDIOVASCULAR DISEASE; HYPERURICEMIA; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPENSITY SCORE; REGISTER; STATISTICAL ANALYSIS; STROKE;

AGED; ALLOPURINOL; CARDIOVASCULAR DISEASES; COHORT STUDIES; DENMARK; FEMALE; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPENSITY SCORE; REGISTRIES; STROKE;

EID: 84958043610     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.11.003     Document Type: Article

References (51)

1. T.R. Mikuls, J.T. Farrar, W.B. Bilker, S. Fernandes, H.R. Schumacher Jr., and K.G. Saag Gout epidemiology: results from the UK General Practice Research Database, 1990-1999 Ann Rheum Dis 64 2 2005 267 272
2. Y. Zhu, B.J. Pandya, and H.K. Choi Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008 Arthritis Rheum 63 10 2011 3136 3141
3. R.T. Keenan, W.R. O'Brien, K.H. Lee, and et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout Am J Med 124 2 2011 155 163
4. E. Krishnan, J.F. Baker, D.E. Furst, and H.R. Schumacher Gout and the risk of acute myocardial infarction Arthritis Rheum 54 8 2006 2688 2696
5. E. Krishnan, K. Svendsen, J.D. Neaton, G. Grandits, and L.H. Kuller MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout Arch Intern Med 168 10 2008 1104 1110
6. S.Y. Kim, J.P. Guevara, K.M. Kim, H.K. Choi, D.F. Heitjan, and D.A. Albert Hyperuricemia and coronary heart disease: a systematic review and meta-analysis Arthritis Care Res 62 2 2010 170 180
7. S.Y. Kim, J.P. Guevara, K.M. Kim, H.K. Choi, D.F. Heitjan, and D.A. Albert Hyperuricemia and risk of stroke: a systematic review and meta-analysis Arthritis Rheum 61 7 2009 885 892
8. A. Shah, and R.T. Keenan Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep 12 2 2010 118 124
9. A. Kelkar, A. Kuo, and W.H. Frishman Allopurinol as a cardiovascular drug Cardiol Rev 19 6 2011 265 271
10. D.I. Feig, B. Soletsky, and R.J. Johnson Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension JAMA 300 8 2008 924 932
11. A. Noman, D.S. Ang, S. Ogston, C.C. Lang, and A.D. Struthers Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial Lancet 375 9732 2010 2161 2167
12. M. Goicoechea, S.G. de Vinuesa, U. Verdalles, and et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk Clin J Am Soc Nephrol 5 8 2010 1388 1393
13. N.S. Rajendra, S. Ireland, J. George, J.J. Belch, C.C. Lang, and A.D. Struthers Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris J Am Coll Cardiol 58 8 2011 820 828
14. J. George, E. Carr, J. Davies, J.J.F. Belch, and A. Struthers High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid Circulation 114 23 2006 2508 2516
15. D. Gaist, H.T. Sorensen, and J. Hallas The Danish prescription registries Dan Med Bull 44 4 1997 445 448
16. K. Helweg-Larsen The Danish Register of Causes of Death Scand J Public Health 39 7 suppl 2011 26 29
17. C.B. Pedersen The Danish Civil Registration System Scand J Public Health 39 7 suppl 2011 22 25
18. L.C. Thygesen, and A.K. Ersboll Danish population-based registers for public health and health-related welfare research: introduction to the supplement Scand J Public Health 39 7 suppl 2011 8 10
19. W. Zhang, M. Doherty, T. Bardin, and et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis 65 10 2006 1312 1324
20. D. Khanna, J.D. Fitzgerald, P.P. Khanna, and et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia Arthritis Care Res 64 10 2012 1431 1446
21. S. Suissa Immortal time bias in observational studies of drug effects Pharmacoepidemiol Drug Saf 16 3 2007 241 249
22. R.J. Glynn, S. Schneeweiss, and T. Sturmer Indications for propensity scores and review of their use in pharmacoepidemiology Basic Clin Pharmacol Toxicol 98 3 2006 253 259
23. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration BMJ 8 308 1994 81 106
24. J.A. Rassen, A.A. Shelat, J. Myers, R.J. Glynn, K.J. Rothman, and S. Schneeweiss One-to-many propensity score matching in cohort studies Pharmacoepidemiol Drug Saf 21 2012 69 80
25. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Available at: http://www2.kidney.org/professionals/KDOQI/guidelines-ckd/toc.htm. Accessed November 23, 2015.
26. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 5 1987 373 383
27. S. Schneeweiss Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics Pharmacoepidemiol Drug Saf 15 5 2006 291 303
28. L.C. Thygesen, C. Daasnes, I. Thaulow, and H. Bronnum-Hansen Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving Scand J Public Health 39 7 suppl 2011 12 16
29. L. Wei, I.S. Mackenzie, Y. Chen, A.D. Struthers, and T.M. MacDonald Impact of allopurinol use on urate concentration and cardiovascular outcome Br J Clin Pharmacol 71 4 2011 600 607
30. V.C. Kok, J.-T. Horng, W.-S. Chang, Y.-F. Hong, and T.-H. Chang Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study PLoS One 9 6 2014 e99102
31. A.J. Luk, G.P. Levin, E.E. Moore, X.H. Zhou, B.R. Kestenbaum, and H.K. Choi Allopurinol and mortality in hyperuricaemic patients Rheumatology 48 7 2009 804 806
32. G. Thanassoulis, J.M. Brophy, H. Richard, and L. Pilote Gout, allopurinol use, and heart failure outcomes Arch Intern Med 170 15 2010 1358 1364
33. B.A. Briesacher, S.E. Andrade, H. Fouayzi, and K.A. Chan Comparison of drug adherence rates among patients with seven different medical conditions Pharmacotherapy 28 4 2008 437 443
34. L.R. Harrold, S.E. Andrade, B.A. Briesacher, and et al. Adherence with urate-lowering therapies for the treatment of gout Arthritis Res Ther 11 2 2009 R46
35. N. Dalbeth, S. Kumar, L. Stamp, and P. Gow Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout J Rheumatol 33 8 2006 1646 1650
36. C.G. Jennings, I.S. Mackenzie, R. Flynn, and et al. Up-titration of allopurinol in patients with gout Semin Arthritis Rheum 44 1 2014 25 30
37. M. Madsen, M. Davidsen, S. Rasmussen, S.Z. Abildstrom, and M. Osler The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry J Clin Epidemiol 56 2 2003 124 130
38. C. Wildenschild, F. Mehnert, R.W. Thomsen, and et al. Registration of acute stroke: validity in the Danish Stroke Registry and the Danish National Registry of Patients Clin Epidemiol 6 2014 27 36
39. E.W. Campion, R.J. Glynn, and L.O. DeLabry Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study Am J Med 82 3 1987 421 426
40. I. Njølstad, E. Arnesen, and P.G. Lund-Larsen Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction: a 12-year follow-up of the Finnmark Study Circulation 93 3 1996 450 456
41. T.M. Palmer, B.G. Nordestgaard, M. Benn, and et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts BMJ 347 2013 f4262
42. Summary of Product Characteristics Allopurinol. 2013. Available at: http://www.tevauk.com/mediafile/id/14734.pdf. Accessed November 23, 2015.
43. H.K. Choi, D.B. Mount, and A.M. Reginato Pathogenesis of gout Ann Intern Med 143 7 2005 499 516
44. J.K. Pai, T. Pischon, J. Ma, and et al. Inflammatory markers and the risk of coronary heart disease in men and women N Engl J Med 351 25 2004 2599 2610
45. A.Y. Tiong, and D. Brieger Inflammation and coronary artery disease Am Heart J 150 1 2005 11 18
46. H.K. Choi, K. Atkinson, E.W. Karlson, W. Willett, and G. Curhan Purine-rich foods, dairy and protein intake, and the risk of gout in men N Engl J Med 350 11 2004 1093 1103
47. H.K. Choi, K. Atkinson, E.W. Karlson, W. Willett, and G. Curhan Alcohol intake and risk of incident gout in men: a prospective study Lancet 363 9417 2004 1277 1281
48. R.J. Glynn, E.L. Knight, R. Levin, and J. Avorn Paradoxical relations of drug treatment with mortality in older persons Epidemiol Camb Mass 12 6 2001 682 689
49. S. Suissa Immeasurable time bias in observational studies of drug effects on mortality Am J Epidemiol 168 3 2008 329 335
50. WHO Collaborating Centre for Drug Statistics Methodology; Norwegian Institute of Public Health Guidelines for ATC Classification and DDD Assignment 2011 2010 WHO Collaborating Centre for Drug Statistics Methodology Oslo, Norway
51. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration BMJ 8 308 1994 81 106